Several trials have shown that transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) yield non-inferior short- and mid-term clinical outcomes in low surgical risk patients. However, information on the health status achieved by these patients is lacking.
To compare the...
A. Phoksiri, A. Maznyczka, M. Savontaus et al.· European Heart Journal· 1 citation
BACKGROUND
Most evidence for transcatheter aortic valve replacement (TAVR) for valve-in-valve procedures comes from balloon-expandable and supra-annular self-expanding valves. However, data on intra-annular self-expanding valves remain limited. The objectives of this registry were to evaluate the short- and midterm out...
Jorge F. Chavez, G. Tirado-Conte, Y. Kobari et al.· Journal of the American Hear...· 0 citations
BACKGROUND
The JenaValve Trilogy Transcatheter Heart Valve System (Trilogy) is a CE-marked transcatheter aortic valve replacement device designed for the treatment of symptomatic aortic regurgitation. Despite its unique indication, data from large cohorts remain limited. This study aimed to evaluate procedural characte...
H. Wienemann, Sara Yousefzada, M. Rogmann et al.· Circulation. Cardiovascular...· 0 citations
TTVR with the LuX-Valve Plus system to treat patients with severe or greater symptomatic TR and a large tricuspid annulus was associated with high intraprocedural and 30-day clinical success rates, significant TR reduction and functional improvement, and low permanent pacemaker implantation rates.
O. de Backer, Y. Lim, R. von Bardeleben et al.· EuroIntervention· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.